SIRT Is More Cost-Effective Than Sorafenib in Locally Advanced HCC
Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.
Hepatocellular Carcinoma
Atezolizumab/Bevacizumab Doublet Provides Longest OS Seen in Advanced HCC
The updated CR rate was 8.0% compared with 5.5% in the primary analysis.
Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
MIV-818 Shows Antitumor Activity in Hepatobiliary Malignancies
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
Post Hoc Analysis of KEYNOTE-240 Study Confirms Prognostic Association Between Time of Pembrolizumab Response, OS Benefit
This post hoc analysis of KEYNOTE-240 was performed to determine whether objective response at landmark is prognostic of longer survival after landmark time.
Tivozanib and Durvalumab Doublet Regimen Is Well-Tolerated in HCC
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
Improved Outcomes With Cabozantinib in HCC Across All Baseline AFP Levels
Cabozantinib prolonged survival compared with placebo regardless of baseline AFP levels. Lower baseline AFP levels associated with the longest survival.
Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
-
Loading...
-
Loading...
Next post in ASCO 2020 HCC In-Depth
